High Coexpression of Both EGFR and IGF1R Correlates With Poor Patient Prognosis in Resected Non–Small-Cell Lung Cancer
Authors:
- 1 January 2014
- journal article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 15 (1) , 58-66
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Screening for Epidermal Growth Factor Receptor Mutations in Lung CancerNew England Journal of Medicine, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialThe Lancet, 2009
- Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future DirectionsJournal of Clinical Oncology, 2005
- Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancerBritish Journal of Cancer, 2004
- Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer TreatmentJNCI: Journal of the National Cancer Institute, 2003
- Immunocytochemical markers in stage I lung cancer: relevance to prognosis.Journal of Clinical Oncology, 1997
- Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomasJournal of Cancer Research and Clinical Oncology, 1993
- Signal transduction by receptors with tyrosine kinase activityCell, 1990
- Epidermal growth factor receptors in non-small cell lung cancerBritish Journal of Cancer, 1987